1. Home
  2. GSIW vs CVKD Comparison

GSIW vs CVKD Comparison

Compare GSIW & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GSIW
  • CVKD
  • Stock Information
  • Founded
  • GSIW 2016
  • CVKD 2022
  • Country
  • GSIW Hong Kong
  • CVKD United States
  • Employees
  • GSIW N/A
  • CVKD N/A
  • Industry
  • GSIW
  • CVKD Medicinal Chemicals and Botanical Products
  • Sector
  • GSIW
  • CVKD Health Care
  • Exchange
  • GSIW Nasdaq
  • CVKD Nasdaq
  • Market Cap
  • GSIW 27.2M
  • CVKD 29.5M
  • IPO Year
  • GSIW 2023
  • CVKD 2023
  • Fundamental
  • Price
  • GSIW $1.63
  • CVKD $11.17
  • Analyst Decision
  • GSIW
  • CVKD Strong Buy
  • Analyst Count
  • GSIW 0
  • CVKD 1
  • Target Price
  • GSIW N/A
  • CVKD $32.00
  • AVG Volume (30 Days)
  • GSIW 2.6M
  • CVKD 35.1K
  • Earning Date
  • GSIW 01-01-0001
  • CVKD 08-06-2025
  • Dividend Yield
  • GSIW N/A
  • CVKD N/A
  • EPS Growth
  • GSIW N/A
  • CVKD N/A
  • EPS
  • GSIW N/A
  • CVKD N/A
  • Revenue
  • GSIW $1,313,795.00
  • CVKD N/A
  • Revenue This Year
  • GSIW N/A
  • CVKD N/A
  • Revenue Next Year
  • GSIW N/A
  • CVKD N/A
  • P/E Ratio
  • GSIW N/A
  • CVKD N/A
  • Revenue Growth
  • GSIW N/A
  • CVKD N/A
  • 52 Week Low
  • GSIW $0.35
  • CVKD $5.70
  • 52 Week High
  • GSIW $12.30
  • CVKD $22.90
  • Technical
  • Relative Strength Index (RSI)
  • GSIW 72.13
  • CVKD 36.41
  • Support Level
  • GSIW $1.26
  • CVKD $12.27
  • Resistance Level
  • GSIW $1.66
  • CVKD $13.63
  • Average True Range (ATR)
  • GSIW 0.14
  • CVKD 1.02
  • MACD
  • GSIW -0.02
  • CVKD 0.07
  • Stochastic Oscillator
  • GSIW 92.25
  • CVKD 31.21

About GSIW Garden Stage Limited

Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: a) I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong, and b) I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.

Share on Social Networks: